Invasive fungal infections: Cryptococcosis

Seminars in Respiratory and Critical Care Medicine

Volumn 18, Issue 3, 1997, Pages 249-257

  Mundy, Linda M ^a   Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cryptococcosis; Prophylaxis; Treatment; Virulence

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR; CYTOKINE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; FUNGUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 8; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LUNG MYCOSIS; MENINGOENCEPHALITIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030789365     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1070994     Document Type: Conference Paper

References (105)

1. Duperval R, Hermans PE, Brewer NS, et al. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 1977; 72:13-19
2. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City Clin Infect Dis 1994;19:1029-33
3. Sehk RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV injection in the United States from 1987 to 1992. Ann Intern Med 1995; 123:933-6
4. McNeil JI, Kan VL. Decline in the incidence of cryptococcosis among HIV-infected patients. J Acquir Immune Defic Syndr Human Retrovirol 1995;9:206-8 (Letter)
5. Manfredi R, Rezza G, Coronado VG, et al. Is AIDS-related cryptococcosis more frequent among men? AIDS 1995;9: 397-8
6. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9
7. Perfect JR, Granger DL, Durack DT. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis 1987;156:316-23
8. Evans EE. The antigenic composition of Cryptococcus neoformans. A serologic classification by means of the capsular agglutinations. J Immunol 1950;64:423-30
9. Kwon-Chung KJ, Kozel TR, Edman JC, et al. Recent advances in biology and immunolgy of Cryptococcus neoformans. J Med Vet Mycol 1992;30:133-42
10. + T-cells. J Exp Med 1991;173:793-800
11. Flesch IE, Schwamberger G, Kaufman SH. Fungicidal activity of IFN-gamma activated macrophages: extracellular killing of Cryptococcus neoformans. J Immunol 1989;142: 3219-24
12. Roseff SA, Levitzu SM. Effect of endothelial cells on phagocyte-mediated anticryptococcal activity. Infect Immun 1993;61:3818-24
13. Salkowski CA, Balish E. Role of natural killer cells in resistance to systemic cryptococcosis. J Leuk Biol 1991;50: 151-9
14. Levitz SM, Dupont MP. Phenotypic and functional characterization of human leukocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest 1993;91:1490-8
15. Miller MF, Mitchell TG, Storkus WJ, et al. Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun 1990;58: 639-45
16. Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 1995;63:573-9
17. Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986;51:218-23
18. Rhodes JC, Polacheck I, Kwon-Chung KJ. Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans. Infect Immun 1982;36:1175-84
19. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-18
20. Gadebusch HH. Passive immunization against Cryptococcus neoformans. Proc Soc Exp Biol Med 1958;98:611-14
21. MukherjeeJ, Lee S, Scharff MD, et al. Monoclonal antibodies to Cryptococcus neoformans capsulai polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994;62:1079-88
22. Mukherjee J, Scharff MD, Casadevall A, Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992;60:4534-41
23. Restrepo BI, Barbour AG. Cloning of 18S and 25S rDNAs from the pathogenic fungus Cryptococcus neoformans. J Bacteriol 1989;171:5596-600
24. Wickes BL, Moore TDE, Kwon-Chung KJ. Comparison of the electrophoretic karyotypes and chromosomal location of ten genes in the two varieties of Cryptococcus neoformans. Microbiology 1994;140:543-50
25. Perfect JR, Toffaletti DL, Rude TH. The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid. Infect Immun 1993;61:4446-51
26. Parker AR, Moore TDE, Edman JC, et al. Cloning sequence analysis and expression of the gene encoding imidazole glycerol phosphate dehydratase in Cryptococcus neoformans. Gene 1994;145:135-8
27. Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence Mol Cell Biol 1994;14:4912-19
28. Williamson PR. Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase. J Bacteriol 1994;176:656-64
29. Perfect JR, Rude TH, Penning LM, et al. Cloning of a Cryptococcus neoformans mannitol dehydrogenase gene. Congr Irit Soc Human Animal Mycol PSL. 45:731991 (Abstract)
30. Lodge JK, Johnson RL, Weinberg RA, et al. Comparison of myristoyl-CoA:protein N-myristoyltransferases from three pathogenic fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans J Biol Chem 1994;269:2996-3009
31. Cox GM, Rude TH, Dykstra CC, et al. Actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. J Med Vet Mycol 1995;33:261-6
32. Cruz MC, Bartlett MS, Edlind TD. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to antihelmintic benzimidazoles. Antimicrobial Agents and Chemotherapy 1994;38:378-80
33. Perfect JR, Rude TH, Penning LM, et al. Cloning the Cryptococcus neoformans TRP1 gene by complementation in Saccharomyces cerevisiae. Gene 1992;122:213-17
34. Moore TDE, Edman JC. The a mating type locus of Cryptococcus neoformans contains a peptide pheromone gene. Mol Cell Biol 1993;13:1962-70
35. Livi LL, Edman U, Schneider GP, et al. Cloning, expression and characterization of thymidylate synthase from Cryptococcus neoformans. Gene 1994;150:221-6
36. Tolkacheva T, McNamara P, Piekarz E, et al. Cloning of a Cryptococcus neoformans gene, GPA1, encoding a G-protein a subunit homolog. Infect Immun 1994;62:2849-56
37. Jacobson ES, Ayers DJ, Harrell AC. Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans. J Bacteriol 1982;150:1292-6
38. Still CN, Jacobson ES. Recombinational mapping of capsule mutations in Cryptncoccus neoformans. J Bacteriol 1983;156:460-2
39. Granger DL, Perfect JR, Durack DT. Virulence of Cryptococcus neoformans: regulation of capsule synthesis by carbon dioxide. J Clin Invest 1985;76:508-16
40. Vartivarian SE, Anaissie EJ, Cowart RE, et al. Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis 1993;167:186-90
41. Pettoello-Mantovani M, Casadevall A, Kollmann TR, et al. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 1992;339:21-3
42. Pettoello-Mantovani M, Casadevall A, Smarnworawong P, Goldstein H, et al. Enhancement of HIV type l1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res Human Retrovirol 1994;10:1079-87
43. Evans EE, Kessel JF. The antigenic composition of Cryptococcus neoformans. Serologic studies with the capsular polysaccharide. J Immun 1951;67:109-14
44. Vogel RA. The indirect fluorescent antibody test for the detection of antibody in human cryptococcal disease. J Infect Dis 1966;116:573-80
45. Murphy JW, Mosley RL, Cherniak R, et al. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens Infect Immun 1988;56:424-31
46. Cherniak R, Reiss E, Slodki ME, et al. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype. Ann Mol Immun 1980;17:1025
47. Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 1995;63:3131-6
48. Lee SC, Casadevall A. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clin Infect Dis 1996;23:194-5
49. Kwon-Chung KJ, Bennett JE. Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol 1978;108: 337-41
50. Kwon-Chung KJ, Edman JC, Wickes BL. Genetic association of mating types and virulence in Cryptococcus neuformans. Infect Immun 1992;60:602-5
51. Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966;94:236-43
52. Driver JA, Saunders CA, Heinze-Lacey B, et al. Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Human Retrovirol 1995;9:168-71
53. Clark RA, Greer DL, Valainis GT, et al. Cryptococcus neoformans pulmonary infection in HW-1-infected patients. J Acquir Immune Defic Syndr Human Retrovirol 1990;3: 480-4
54. Cameron ML, Bartlett JA, Gallis HA, et al. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991;13:64-7
55. Clark RA, Greer DL, Atkinson W, et al. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990;12: 768-77
56. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptocuccus neoformans. Clin Microbiol Rev 1995;8:515-48 (Review)
57. Lehmann PF, Morgan RJ, Freimer EH. Infection with Cryptococcus neoformans van gattii leading to a pulmonary cryptococcoma and meningitis. J Infect 1984;9:301-6
58. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981;94:611-16
59. Diamond RD Effects of stimulation and suppression of cell-mediated immunity on cryptococcosis. Infect Immun 1977;17:187-94
60. Diamond RD, May JE, Kane MA, et al. The role of the classical and alternative complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974; 112:2260-70
61. Ennis DM, Saag MS. Cryptococcal meningitis in AIDS. Hospital Pract 1993;28:99-112
62. Haynes KA, Sullivan DJ, Coleman DC, et al. Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting. J Clin Microbiol 1995;33:99-102
63. Spitzer ED, Spitzer SG, Freundlich LF, et al. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993;341:595-6
64. Perfect JR, Durack DT, Gallis HA. Cryptococcemia. Medicine 1983;62:98-109
65. Pema K, Diaz J, Guerra LG, et al. Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras. Arch Intern Med 1994;154: 1032-4 (Review)
66. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989;111: 125-8
67. Currie BP, Freundlich LF, Soto MA, et al. False-negative cerebrospinal fluid Cryptococcal latex agglutination tests for patients with culture-positive Cryptococcal meningitis. J Clin Microbiol 1993;31:2519-22
68. Tanner DC, Weinstein MP, Fedoview B, et al. Comparison of commercial kits for detection of Cryptococcal antigen. J Clin Microbiol 1993;32:1680-9
69. van der Horst C, Saag M, Cloud G, et al. Randomized double blind comparison of amphotericin B (AMB) plus flucytosine to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute Cryptococcal meningitis in patients with AIDS. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 (Abstract)
70. Saag MS, the NIAID Mycoses Study Group. Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 (Abstract)
71. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated Cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9
72. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326: 793-8
73. Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of Cryptococcal antigen in serum and cerebrospinal fluid- value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92
74. Larsen RA, Bozzette S, Jones BE, et al. Fluconazole combined with flucytosine for treatment of Cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5
75. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-35
76. Dismukes WE. Cryptococcal meningitis patients with AIDS. J Infect Dis 1988;157:624-8
77. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med 1974;80:176-81
78. Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992;14(Suppl 1):S54-9 (Review)
79. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1): S103-7 (Review)
80. Dimino-Emme L, Gurevitch AW. Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 1995;32(Pt 2):844-50
81. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995;345:548-52
82. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173: 219-25
83. Powderly WG. Recent advances in die management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(Suppl 2):S119-23 (Review)
84. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neofarmans. EurJ Immunol 1992;22:1447-54
85. Uchida K, Yamamoto Y, Klein TW, et al. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992;30:293-300
86. Joly V, Saint-Julien L, Carbon C, et al. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-4
87. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-4
88. Van der Meer JWM, Vogels MTE, Kullberg BJ. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 1994;7:161-7
89. van 't Wout JW, Van der Meer JWM, Barza M, et al. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin-1. Eur J Immunol 1988;18:1143-6
90. Levitz SM. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun 1991;59:3393-7
91. Casadevall A, Mukherjee J, Scharff MD. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods 1992;154:27-35
92. Dromer F, Gueho E, Ronin O, et al. Serotyping of Cryptococcus neoformans by uising a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol 1993; 31:359-65
93. Mukherjee J, Feldmesser M, Scharff MD, et al. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother 1995;39:1398-1405
94. Mukherjee J, Zuckier LS, Scharff MD, et al. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994; 38:580-7
95. Gordon MA, Casadevall A. Serum therapy for cryptococcal meningitis. Clin Infect Dis 1995;21:1477-9
96. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-61
97. Henderson DK, Bennett JE, Huber MA. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest 1982;69:1185-90
98. Henderson DK, Kan VL, Bennett JE. Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin Exp Immunol 1986;65:639-46
99. Zebedee SL, Koduri RK, Mukherjee J, et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 1994;38:1507-14
100. Devi SJN, Schneerson R, Egan W, et al. Cryptococcus neoformans serotype A glucuronoxylomannan protein conjugate vaccine. synthesis, characterization and immunogenicity. Infect Immun 1991;59:3700
101. Mukherjee J, Casadevall A, Scharff MD. Molecular characterisation of the humoral responses to Cryptococcus, neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med 1993;177:1105-16
102. Nussbaum G, Yuan RR, Casadevall A, et al. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med 1996;183:1905-9
103. Ellis D, Pfeiffer T. The ecology of Cryptococcus neoformans. EurJ Epidemiol 1992;8:321-5 (Review)
104. Pfeiffer T, Ellis D. Environmental isolation of Cryptococcus neoformans var. gattii from California. J Infect Dis 1991; 163:929-30
105. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995;21:28-34t